$776.31
0.58%
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US75886F1075
Symbol
REGN

Regeneron Pharmaceuticals Stock price

$776.31
+34.31 4.62% 1M
+228.57 41.73% 6M
+4.44 0.58% YTD
+61.12 8.55% 1Y
+54.82 7.60% 3Y
+293.45 60.77% 5Y
+259.76 50.29% 10Y
+760.41 4,782.45% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+4.44 0.58%
ISIN
US75886F1075
Symbol
REGN
Industry

New AI Insights on Regeneron Pharmaceuticals Insights AI Insights on Regeneron Pharmaceuticals

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$81.6b
Enterprise Value
$75.9b
Net debt
positive
Cash
$8.4b
Shares outstanding
105.3m
Valuation (TTM | estimate)
P/E
18.2 | 17.7
P/S
5.7 | 5.6
EV/Sales
5.3 | 5.2
EV/FCF
19.5
P/B
2.6
Dividends
DPS
$3.52
Yield 1Y | 5Y
0.5% | 0.1%
Growth 1Y | 5Y
100.0% | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
1 Year
Financials (TTM | estimate)
Revenue
$14.2b | $14.5b
EBITDA
$4.5b | $5.0b
EBIT
$3.9b | $4.8b
Net Income
$4.6b | $4.6b
Free Cash Flow
$3.9b
Growth (TTM | estimate)
Revenue
2.9% | 2.0%
EBITDA
-4.4% | 7.3%
EBIT
-6.2% | 13.6%
Net Income
-1.6% | 4.8%
Free Cash Flow
16.9%
Margin (TTM | estimate)
Gross
86.3%
EBITDA
31.3% | 34.8%
EBIT
27.6%
Net
32.1% | 31.9%
Free Cash Flow
27.2%
Financial Health
Equity Ratio
77.7%
Return on Equity
15.0%
ROCE
11.0%
ROIC
11.7%
Debt/Equity
0.1
More
EPS
$42.7
FCF per Share
$36.9
Short interest
2.8%
Employees
15k
Rev per Employee
$940.0k
Show more

Create a Free Account to create an Regeneron Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Regeneron Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

36 Analysts have issued a Regeneron Pharmaceuticals forecast:

27x Buy
75%
8x Hold
22%
1x Sell
3%

Analyst Opinions

36 Analysts have issued a Regeneron Pharmaceuticals forecast:

Buy
75%
Hold
22%
Sell
3%

Financial data from Regeneron Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
14,248 14,248
3% 3%
100%
- Direct Costs 1,955 1,955
7% 7%
14%
12,293 12,293
2% 2%
86%
- Selling and Administrative Expenses 3,197 3,197
10% 10%
22%
- Research and Development Expense 5,157 5,157
5% 5%
36%
4,459 4,459
4% 4%
31%
- Depreciation and Amortization 525 525
12% 12%
4%
EBIT (Operating Income) EBIT 3,934 3,934
6% 6%
28%
Net Profit 4,578 4,578
2% 2%
32%

In millions USD.

Don't miss a Thing! We will send you all news about Regeneron Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Regeneron Pharmaceuticals Stock News

Neutral
GlobeNewsWire
13 days ago
Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function compared to placebo (by 4.68% to 5.32%)    Dupixent is the first and only biologic medicine to demonstrate improved lung function in this ...
Neutral
GlobeNewsWire
13 days ago
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo
Neutral
GlobeNewsWire
13 days ago
TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron...
More Regeneron Pharmaceuticals News

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Head office United States
CEO Leonard Schleifer
Employees 15,158
Founded 1988
Website www.regeneron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today